Franklin, Tenn.-based Acadia Healthcare will participate in a clinical trial for intranasal ketamine.
The randomized, double-blind, placebo-controlled study is intended to evaluate the effectiveness of the drug for treating suicidal ideation and major depression, Acadia said Sept. 14. Select Acadia hospitals will be included.
Patients who exhibit specific symptoms will be eligible for enrollment in the study, Acadia said.